These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20024536)

  • 21. Current and emerging second-generation triptans in acute migraine therapy: a comparative review.
    Deleu D; Hanssens Y
    J Clin Pharmacol; 2000 Jul; 40(7):687-700. PubMed ID: 10883409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiple attack study on the available triptans in Italy versus placebo.
    Vollono C; Capuano A; Mei D; Ferraro D; Pierguidi L; Evangelista M; Di Trapani G
    Eur J Neurol; 2005 Jul; 12(7):557-63. PubMed ID: 15958097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Zolmitriptan].
    Monseu G; Sternon J
    Rev Med Brux; 1998 Dec; 19(6):495-9. PubMed ID: 9916496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Migraine headache.
    Morillo LE
    Clin Evid; 2004 Jun; (11):1696-719. PubMed ID: 15652076
    [No Abstract]   [Full Text] [Related]  

  • 25. Ergot of rye-the first specific for migraine.
    Eadie MJ
    J Clin Neurosci; 2004 Jan; 11(1):4-7. PubMed ID: 14642357
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of rizatriptan and other triptans on the nausea symptom of migraine: a post hoc analysis.
    Lipton RB; Pascual J; Goadsby PJ; Massiou H; McCarroll KA; Vandormael K; Jiang K; Lines CR
    Headache; 2001 Sep; 41(8):754-63. PubMed ID: 11576198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rizatriptan: a pharmacoeconomic review of its use in the acute treatment of migraine.
    McCormack PL; Foster RH
    Pharmacoeconomics; 2005; 23(12):1283-98. PubMed ID: 16336021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Triptan use in Australia 1997-2015: A pharmacoepidemiological study.
    Eyre BLKD; Eadie MJ; van Driel ML; Ross-Lee L; Hollingworth SA
    Acta Neurol Scand; 2017 Aug; 136(2):155-159. PubMed ID: 28093722
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD; Subedi PR; Healey PJ; Sanchez RJ
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Economic evaluation of acute migraine attack treatment with triptans in Spain].
    Gracia-Naya M; Rejas Gutiérrez J; Latorre Jiménez A; González Garcia P
    Neurologia; 2005 Apr; 20(3):121-32. PubMed ID: 15815947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maximum effect of triptans in migraine? A comment.
    Tfelt-Hansen P
    Cephalalgia; 2008 Jul; 28(7):767-8. PubMed ID: 18547214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current topics: expectation for new triptans].
    Hashimoto S; Iwata M
    Nihon Naika Gakkai Zasshi; 2001 Apr; 90(4):654-8. PubMed ID: 11391915
    [No Abstract]   [Full Text] [Related]  

  • 33. Migraine headache.
    Morillo LE
    Clin Evid; 2003 Dec; (10):1547-65. PubMed ID: 15555160
    [No Abstract]   [Full Text] [Related]  

  • 34. Hair analysis for detection of triptans occasionally used or overused by migraine patients-a pilot study.
    Ferrari A; Baraldi C; Licata M; Vandelli D; Marchesi F; Palazzoli F; Verri P; Rustichelli C; Giuliani E; Silingardi E
    Eur J Clin Pharmacol; 2016 Sep; 72(9):1075-81. PubMed ID: 27245458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eletriptan review.
    Färkkilä M; Kallela M
    Expert Opin Pharmacother; 2005 Apr; 6(4):625-30. PubMed ID: 15934888
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Headache currents commentary.
    Peatfield R
    Headache; 2012 Apr; 52(4):715. PubMed ID: 22414189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
    Dahlöf C; Maassen Van Den Brink A
    Headache; 2012 Apr; 52(4):707-14. PubMed ID: 22444161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Reclassifying Triptans in Australia: Application of an Economic Evaluation Approach to Regulatory Decisions.
    Parkinson B; Gumbie M; Cutler H; Gauld N; Mumford V; Haywood P
    Value Health; 2019 Mar; 22(3):293-302. PubMed ID: 30832967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD; Feleppa M; Tepper SJ; Volcy M; Rapoport AM; Bigal ME
    Headache; 2004; 44(7):661-8. PubMed ID: 15209687
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials.
    Ferrari MD; Roon KI; Lipton RB; Goadsby PJ
    Lancet; 2001 Nov; 358(9294):1668-75. PubMed ID: 11728541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.